Peptides

Find every peptide in the research library. Each page shows its available local studies or identifies the evidence missing from the packet.

Start with an outcome instead →

30 peptides

01
Tirzepatide

GIP / GLP-1 receptor agonist

47 local study records

Save peptide
02
Semaglutide

GLP-1 receptor agonist

52 local study records

Save peptide
03
BPC-157

Body protection compound 157

46 local study records

Save peptide
04
Retatrutide

Local evidence and research gaps

18 local study records

Save peptide
05
GHK-Cu

Copper tripeptide

23 local study records

Save peptide
06
TB-500

Thymosin beta-4–related products

42 local study records

Save peptide
07
Collagen peptides

Hydrolyzed collagen

57 local study records

Save peptide
08
Tesamorelin

Local evidence and research gaps

15 local study records

Save peptide
09
CJC-1295

Growth hormone–releasing hormone analogue

3 local study records

Save peptide
10
Ipamorelin

Growth hormone secretagogue

3 local study records

Save peptide
11
MOTS-c

MOTS c MOTSc

13 local study records

Save peptide
12
Sermorelin

Local evidence and research gaps

3 local study records

Save peptide
13
PT-141 / bremelanotide

bremelanotide PT141

5 local study records

Save peptide
14
Cagrilintide

CagriSema

9 local study records

Save peptide
15
SS-31 / elamipretide

elamipretide SS31

20 local study records

Save peptide
16
KPV

Local evidence and research gaps

2 local study records

Save peptide
17
Semax

Local evidence and research gaps

15 local study records

Save peptide
18
Selank

Local evidence and research gaps

3 local study records

Save peptide
19
Epitalon / Epithalon

Epithalon

4 local study records

Save peptide
20
Thymosin alpha-1

thymosin alpha 1

20 local study records

Save peptide
21
AOD-9604

AOD9604

Topic-specific study record: NOT IN CORPUS

Save peptide
22
Melanotan II

Melanotan 2

5 local study records

Save peptide
23
DSIP

Local evidence and research gaps

3 local study records

Save peptide
24
IGF-1 LR3

IGF1 LR3

Topic-specific study record: NOT IN CORPUS

Save peptide
25
GHRP-2

GHRP2

7 local study records

Save peptide
26
GHRP-6

GHRP6

7 local study records

Save peptide
27
Kisspeptin-10

kisspeptin 10

8 local study records

Save peptide
28
Oxytocin

Local evidence and research gaps

26 local study records

Save peptide
29
LL-37

LL37

19 local study records

Save peptide
30
Hexarelin

Local evidence and research gaps

14 local study records

Save peptide

How strong is the evidence?

Grades describe certainty for a specific outcome. See how we grade.

Questions & answers

Questions from public discussions, answered with research.

Does BPC-157 speed tendon or ligament healing?
Quick answer:

The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[1] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[2] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[2] Pain relief and tissue repair are different outcomes: a report of less pain does not show that a torn tendon has regained its structure or mechanical strength.[1] The rat experiment assessed surgically repaired Achilles tendons, so it also cannot determine whether BPC-157 accelerates recovery from the range of tendon injuries seen in clinical practice.[2]

Study context and limitations
Population
Knee-pain patients and surgically injured rats.[1][2]
Study design
Human case series indirect for structural repair; exploratory rat repair experiment.[1][2]
Outcome
Structural tendon or ligament healing.[1][2]
Formulation / route
Study-specific; no cross-route equivalence assumed.[1][2]
Key limitation
Symptoms and preclinical endpoints do not establish human structural repair.[1][2]
Read in the peptide guide
What does the human knee-pain study show?
Quick answer:

Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[1] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[1] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[1] The finding is therefore a preliminary signal of reported symptom improvement, rather than evidence that BPC-157 treats a defined knee disorder or repairs damaged cartilage.[1]

Study context and limitations
Population
16 contacted patients,12 receiving BPC-157 alone.[1]
Study design
Uncontrolled retrospective case series.[1]
Outcome
Knee-pain symptom relief.[1]
Formulation / route
Study-specific; no cross-route equivalence assumed.[1]
Key limitation
No placebo or objective repair endpoint.[1]
Read in the peptide guide
What evidence supports muscle-injury recovery?
Quick answer:

Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][4] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[5] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][4][5] The experiments address different injuries and treatment conditions, making their results specific to those models rather than a single, established effect on muscle recovery.[3][4][5] They do not answer whether an athlete or a patient undergoing rehabilitation would regain strength sooner, return to activity earlier, or experience fewer complications.[3][4][5]

Study context and limitations
Population
Rats with induced muscle injuries.[3][4][5]
Study design
Controlled rat surgical and crush-injury experiments.[3][4][5]
Outcome
Muscle recovery in people.[3][4][5]
Formulation / route
Study-specific; no cross-route equivalence assumed.[3][4][5]
Key limitation
No direct human muscle-recovery trial in these studies.[3][4][5]
Read in the peptide guide
Does BPC-157 heal the gut or treat inflammatory bowel disease?
Quick answer:

Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8] Damage caused experimentally by concentrated alcohol is a different research problem from treating chronic inflammatory bowel disease in people.[7] The animal results provide a reason to investigate gastrointestinal effects, but the incomplete human report does not establish which patients would benefit, how large the benefit would be, or whether it would persist.[6][7][8]

Study context and limitations
Population
Rat gastric-injury models; separate human ulcerative-colitis abstract.[6][7][8]
Study design
Rat injury experiments; regulatory assessment of an abstract-only human trial.[6][7][8]
Outcome
Human digestive benefit.[6][7][8]
Formulation / route
Study-specific; no cross-route equivalence assumed.[6][7][8]
Key limitation
Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[6][7][8]
Read in the peptide guide
See all questions